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SILDENAFIL AND CELECOXIB INTERACT TO KILL BREAST CANCER CELLS 
By Brittany Binion, MS 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
Virginia Commonwealth University, 2014 
Major Director: Paul Dent, Ph.D. Department of Biochemistry 
 Breast cancer is the second most commonly diagnosed cancer among American women 
and is responsible for the second highest number of cancer-related deaths. Targeted therapeutic 
agents sildenafil, a phosphodiesterase type 5 inhibitor, and celecoxib, a cyclooxygenase-2 
inhibitor, have been used individually in conjunction with other chemotherapeutic agents to 
enhance cell killing in a variety of cancers. Sildenafil when combined with traditional 
chemotherapeutic drugs, such as the taxanes and anthracyclines, or celecoxib combined with 
traditional hormone therapies have been used to increase cytotoxicity and cell killing. The data 
presented here demonstrates that the novel combination of sildenafil and celecoxib work together 
to enhance cell killing in both receptor positive and triple negative breast cancer through the 
induction of autophagy, ER stress, as well as both intrinsic and extrinsic apoptosis.
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Introduction 
Breast Cancer 
 Over 200,000 new cases of invasive breast cancer are diagnosed in the United States each 
year, and approximately 40,000 of the patients diagnosed will die from the disease.
1
 From 2001 
to 2010, the incidence of breast cancer in the United States remained level among women, and 
the mortality rate decreased by 2.0% per year
2
. It has been suggested that at least half of the 
reduction in breast cancer mortality that was observed over the last thirty years is attributable to 
the widespread use of adjuvant therapy.
3
  It is common to classify the disease based upon nodal 
status, tumor grade and size, as well as other prognostic factors such as hormone receptor 
status.
4,5
 These designations are useful, particularly the expression of receptors present in the 
cancer, as they are used to determine potentially effective treatments.  
 The breast cell lines utilized in experiments in this manuscript were ductal carcinomas, 
with differing receptor expression patterns, indicated in table 1. The BT 474 cell line is 
characterized mostly by the overexpression of human epidermal growth factor receptor 2 
(HER2), as it retains functional estrogen receptors (ER) and progesterone receptors (PR).
6,7
 
However, the BT 549 cell line is referred to as triple negative breast cancer (TNBC), as it does 
not express any of the three major receptors used in breast cancer diagnosis.
8
 The absence of ER 
and PR expression has been shown to be associated with early disease recurrence and poor 
survival, and 15% of breast cancers diagnosed worldwide are designated as TNBC .
1, 9, 10, 11, 12 
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Table 1: Cell line receptor expression. A table listing the characteristic receptor expression 
status of the cell lines used in this study. For expression levels, (-) signifies absent, (+) indicates 
expression, (++) signifies overexpression. 
Cell line ER PR HER2 
BT 474 + + ++ 
BT 549 - - - 
 
Conventional Treatment 
 The conventional treatment course for patients with breast cancer typically involve 
surgical removal and a neo-adjuvant (pre-surgery) or more commonly an adjuvant (post-surgery) 
therapy. These adjuvant therapies can include radiation, chemotherapeutics such as 
anthracyclines and taxanes, hormone therapy, targeted therapy, or a combination of treatments.  
 TNBC is highly aggressive, and is responsible for a disproportionate number of 
metastatic disease cases and breast cancer deaths.
13,14,15
  It is typically treated with a combination 
of cytotoxic chemotherapy agents, including the anthracyclines and taxanes.
16
 Commonly there 
is residual disease after treatment of early breast cancer, and these patients have a high risk of 
relapse, with a sharp decrease in survival in the first 3 to 5 years after treatment.
13, 17, 18, 19
  
Conventional treatments for relapsed patients are limited, particularly because standard 
chemotherapeutic regimens containing anthracyclines and taxanes have already been given in the 
adjuvant and neoadjuvant settings, opening up the potential for resistance to drugs already 
administered.
20
  
 Typically, conventional chemotherapy does not have the ability to discriminate between 
normal rapidly dividing cells and cancer cells and has low therapeutic efficacy. In contrast, 
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targeted therapies have specific molecular targets in tumor cells, which act with higher 
specificity and induce less overall toxicity.
21
 Due to these aspects of targeted therapies, they 
represent a more promising approach based on the molecular understanding of tumorigenesis, 
which may potentially replace conventional cytotoxic chemotherapy in the future. The largest 
obstacle in targeted therapies comes from the potential for crosstalk between cellular survival 
pathways, commonly resulting in the activation of alternative pathways,  ultimately leading to 
drug resistance. Therefore, it is becoming more evident that targeted therapeutics used in 
combination may provide a more rational strategy to increase the efficacy of drug treatments in 
cancer patients. 
Hormone and Targeted Therapies 
 Both the ER and the PR play important roles in the physiology of the reproductive tract, 
and have effects on the normal growth of the breast as well as the progression of breast cancer.
22, 
23
 The ER is a hormone-regulated nuclear transcription factor that can induce the expression of a 
number of genes, including that of the PR.
24
 Upon ligand activation, ER binds to estrogen 
response elements on target genes and regulates the transcription of these specific genes, 
including that of the PR.
25
 Due to the complex nature of co-regulatory proteins and extra nuclear 
actions involved in ER signaling, there is a requirement for tight regulation of these factors, with 
dysregulation being implicated in the progression of cancer attributed to the importance of ER in 
growth and survival pathways.
23 
For hormone receptor positive patients, therapeutic strategies 
are commonly directed at inhibiting the actions of ER using selective ER modulators (SERMs), 
targeting ER for degradation with selective ER downregulators (SERDs), or withdrawing 
estrogen via surgical methods (oophorectomy) or medically by aromatase inhibitors in post-
menopausal women.
26
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 Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase gene that 
is amplified and causes overexpression of protein in 20-30% of metastatic breast cancer.
27
 This 
amplification and overexpression is associated with reduced time to progression of the disease as 
well as a reduction in overall survival in breast cancer patients.
28
 The HER2 gene does not need 
to be mutated for oncogenic function, simply the amplification of wild-type HER2 is sufficient to 
produce the oncogenic effects.  
 In HER2 overexpressing cells, excess expression can lead to spontaneous and constitutive 
ligand-independent dimerization, which activates the cytoplasmic kinase region of the 
receptor.
29, 30, 31 
This kinase activation can stimulate autophosphorylation of tyrosine residues 
within the cytoplasmic domain of the receptors and initiate downstream signaling, primarily 
though the AKT and MAPK pathways, ultimately leading to increased proliferation, protein 
synthesis and cell survival.
27
 The PI3K/AKT signaling pathway is a major effector of HER2 
activity; PI3K blockade suppressed tumor growth in multiple models of HER2-overexpressing 
breast cancers.
32, 33
 MAPK signaling appears to contribute to progression of HER2-positive 
breast cancer, with hyper activation of MAPK signaling and resistance to the ER modulator 
tamoxifen seen in HER2 and ER-positive cells.
31 
 Post-surgery, adjuvant treatments for HER2-positive breast cancer patients typically 
involves long-term treatment with trastuzumab (Herceptin), a monoclonal antibody that attaches 
to HER2 receptors on breast cancer cells and blocks them from receiving growth signals. This 
blockade can slow or even stop cancer growth. In the event that the cancer metastasizes, a 
tyrosine kinase inhibitor called lapatinib is used to inhibit receptor signal processes by binding to 
the ATP-binding pocket of the HER2 protein kinase domain.
35
 This prevents 
autophosphorylation and subsequent activation of downstream signaling mechanisms.  
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 Taken together, most common therapies are geared towards directly blocking or 
eliminating receptor activation. However, there is evidence of crosstalk between ER, PR and 
growth factor receptor signaling pathways, especially the epidermal growth factor receptor 
(EGFR) family, as one of the mechanisms for resistance to endocrine therapy in breast cancer.
36, 
37, 38
 Bidirectional crosstalk between ER and growth factor pathways, particularly HER2, result 
in a positive feedback cycle of survival and cell proliferative stimuli.
38
 This indicates that the 
current methods of blocking receptor signaling are no longer as effective, as resistances are 
becoming more commonplace. Drug resistance is also of particular concern for TNBC patients as 
therapies are quite limited for patients experiencing cases of metastasis. This is largely due to a 
lack of targeted therapies available as well as the prevalence for acquired resistance against 
chemotherapies previously administered. 
Sildenafil 
 Phosphodiesterases (PDEs) are a family of enzymes which catalyze the hydrolysis of the 
cyclic nucleotides to their corresponding 5-monophosphate counterparts, leading to a decrease in 
levels of the cyclic nucleotides.
39
 Sildenafil (Viagra) is an oral PDE inhibitor specific to isoform 
5 (PDE5), with selectivity for cyclic guanosine monophosphate (cGMP).
40, 41
 Nitric oxide (NO) 
stimulates the enzyme guanylate cyclase to convert guanosine triphosphate (GTP) to cGMP, with 
high levels of cGMP being responsible for the relaxation of smooth muscle.
42
 Thus, sildenafil 
enhances the actions of the endogenous NO-cGMP pathway, by mediating the elevation of 
cGMP levels due to inhibiting its degradation by PDE5.
43, 44
 Due to the localization of PDE5 in 
the corpus cavernosum, sildenafil is successfully used in the treatment of erectile dysfunction.  
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 It has been demonstrated that hypoxia-induced inhibition of intracellular NO-cGMP 
signaling can lead to a more malignant phenotype in cancer cells, including chemoresistance and 
evasion of immune detection.
45, 46
 PDE-specific inhibition decreased hypoxia-mediated chemo 
resistance, confirming the potential clinical utilization of enhancing NO-cGMP signaling to 
chemo sensitizes cancer cells.
45,46, 47 
Thus, PDE5 inhibitors may be used as an anticancer therapy, 
due to their essential role in regulating cGMP, which as a second messenger causes a reduction 
in cell growth as well as the induction of apoptosis.
48, 49, 50 
  It has also been demonstrated that when paired with standard of care chemotherapy 
treatments, such as doxorubicin, sildenafil mediates a cardio protective effect through the NO-
cGMP pathway involving the enhanced expression of nitric oxide synthase (NOS).
51
 This 
protective effect offsets one of the biggest concerns with doxorubicin treatment as well as 
enhancing doxorubicin induced cell death through apoptosis, particularly the extrinsic pathway 
through death receptors.
51, 52
 
 Sildenafil is generally administered as a single 50 milligram (mg) dose per day as needed, 
and can be adjusted up to 100 mg or down to 25 mg. It is well tolerated by patients, with the 
occurrence of mild side effects such as headache, flushing, dyspepsia, nasal congestion, urinary 
tract infection, abnormal vision, diarrhea, dizziness, and rash. 
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Figure 1: Chemical structure of sildenafil
72 
Celecoxib 
 Celecoxib (Celebrex) was the first specific inhibitor of cyclooxygenase-2 (Cox-2) 
approved by the US Food and Drug Administration (FDA) in December of 1998 to treat patients 
with rheumatoid arthritis and osteoarthritis.
53
 The purpose of Celecoxib was to produce a non-
steroidal anti-inflammatory drug (NSAID) that had little to no effects on the gastrointestinal 
system or the kidneys, which are commonly negatively affected by NSAIDS.  
 Patients taking celecoxib have an initial recommended dosage of 200mg daily for 
osteoarthritis and 400 mg daily for rheumatoid arthritis.
54
 Common side effects are relatively 
mild, and include abdominal pain, diarrhea, dyspepsia, flatulence, dizziness, upper respiratory 
tract infection and rash, with a potential for increased cardiovascular risks.
55
  
 The COX enzymes catalyze the synthesis of prostaglandins (PGs) from arachidonic acid, 
which are important messengers involved in the process of inflammation.
56
 There are two 
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isoforms of COX, with COX-1 being expressed in most tissues and producing PGs that are 
responsible for the control of normal physiological functions such as the maintenance of gastric 
mucosa.
56
 Thus the gastric side effects caused by traditional NSAIDs that non-selectively inhibit 
both isoforms of COX are likely through the inhibition of COX-1, which mediates 
gastroprotective PGs.  In contrast, COX-2 is not found in most normal tissues and is induced by 
inflammatory stimuli, which leads to enhanced synthesis of PGs in neoplastic and inflamed 
tissues.
56
 The selectivity of COX inhibitors arises from a single substitution in the NSAID 
binding site, which produces a void volume to the side of the central active-site channel; 
compounds that bind in this additional space inhibit COX-2 selectively.
57 
 It was noted that long term use of NSAIDs appeared to reduce the risk of developing 
cancer.
56, 58
 COX2 is commonly observed to be upregulated in cancer, including breast, and 
administration of celecoxib caused a greater suppression of the incidence of malignant breast 
tumors when compared to the administration of traditional NSAIDs.
59, 60
 It was indicated that the 
increase in tumorigenic potential by COX2 overexpression was associated with a resistance to 
apoptosis through the overproduction of PGs, and celecoxib was therefore inducing apoptosis.
61
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Figure 2: Chemical structure of celecoxib.
73 
Apoptosis: Intrinsic and Extrinsic Pathways 
 Apoptosis is a form of programmed cell death that is intimately involved in the 
development and homeostasis of normal tissues.
62
 Most notably, apoptosis is characterized by 
morphological changes that take place, such as cell shrinkage, membrane blebbing, nucleus 
fragmentation, chromatin condensation and DNA degradation.
63, 64, 65
 Within the designation of 
apoptosis there are two distinct pathways: the extrinsic, or death receptor pathway, and the 
intrinsic, or mitochondrial pathway (figure 3). It is suggested that these two pathways are 
connected, and have the ability influence each other.
63
 Both the intrinsic and extrinsic pathways 
ultimately converge on the activation of specific intracellular proteases, known as the caspase 
family, that are responsible for cleaving proteins adjacent to aspartate residues. These proteases 
are commonly categorized as initiators or executioners and are synthesized as inactive zymogens 
that become activated through cleavage by their upstream modulators.
63, 66
 Caspase 3 is the most 
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important executioner, as it is the link between the two pathways; it is activated by any of the 
initiator caspases (8, 9 and 10). Executioner caspases (3, 6 and 7) cleave and affect a multitude of 
substrates, including cytoskeletal and nuclear proteins, as well as activating other proteases and 
endonucleases involved in protein degradation and DNA fragmentation.
63,66
  
 The intrinsic pathway is strictly regulated by the B-cell lymphoma-2 (Bcl-2) family of 
proteins.
63, 66
 This family contains three different classes of proteins: the anti-apoptotic group I, 
the pro-apoptotic group II, and group III proteins that are responsible for binding and regulating 
the activity of anti-apoptotic group II proteins. The group I family members such as Bcl-2, B-cell 
lymphoma-extra large (Bcl-xL) and myeloid cell leukemia-1 (Mcl-1) bind directly to and inhibit 
pro-apoptiotic group II family members, that include Bcl-2-associated X protein (Bax) and Bcl-2 
homologous antagonist/killer (Bak). The group III family members that include p53 unregulated 
modulator of apoptosis (Puma), NADPH oxidase activator (Noxa), BH3 interacting domain 
death agonist (BID) and Bcl-2 interacting mediator of cell death (BIM) all interact with the 
group II pro-apoptotic members as well, however they induce the insertion of the group II 
proteins into the mitochondrial membrane.
63, 66, 67
 Recently studies have demonstrated that the 
tumor suppressor p53 may be implicated in the synthesis of Puma and Noxa, providing a link 
between DNA damage and apoptotic cell death.
68, 69
 
 Various stimuli, including viral infection, DNA damage and the absence of particular 
growth factors such as hormones and cytokines lead to the activation of the intrinsic pathway. 
Upon exposure to these stimuli, Bax and Bak are inserted in to the mitochondrial outer 
membrane, leading to membrane permeabilization via the formation of pores. The formation of 
these pores leads to the release of cytochrome-c and other various pro-apoptotic proteins that 
include caspase-activated deoxyribonuclease (CAD), apoptosis-inducing factor (AIF) and 
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endonuclease G, from the inter-membrane space in the mitochondria to the cytosol.
63, 66
 Once in 
the cytosol, cytochrome-c binds to apoptotic protease-activating factor-1 (Apaf-1), which then 
binds pro-caspase 9 to form a complex called the apoptosome that includes multiple Apaf-1 and 
procaspase 9 molecules.
70
 The binding event induces a conformational change and leads to the 
activation of caspase 9, that goes on to proteolytically activate the executioner caspase 3.
63, 66
 
Once activated, caspase 3 goes on to activate caspase 6 as well as CAD through cleavage of its 
inhibitor (ICAD).
70
 CAD, with AIF and endonuclease G, translocates to the nucleus where they 
all contribute to DNA fragmentation.
63, 65, 66
 
 Binding of ligands from the tumor necrosis factor (TNF) family to death receptors leads 
to the activation of the extrinsic pathway. These TNF family receptors consist of a cysteine-rich 
extracellular domain for ligand binding and a cytoplasmic domain of 80 amino acids, termed the 
death domain (DD), which is involved in transducing the signal into the cell.
63, 65, 67
  
 The best characterized member of this receptor family is the Fas receptor, also called 
cluster of differentiation 96 (CD95). CD95 is a 45 kDa trans-membrane protein that upon 
binding with its ligand, FasL, induces a conformational change allowing for the recruitment of an 
adaptor protein called Fas-associated death domain (FADD). FADD itself contains another key 
motif, the death-effector domain (DED) that binds complementary DED domains on initiator 
caspases 8 and 10.
63, 65, 67
 This entire intracellular complex is titled the death-inducing signaling 
complex (DISC) and its formation leads to the auto-proteolytic cleavage and activation of 
caspases 8 and 10.The activation of these initiatior caspases then causes the activation of the 
executioner caspases 3 and 7, that are responsible for the induction of the apoptotic response.
63,65, 
67 
 This pathway can be inhibited by FLICE-inhibitory proteins (FLIP), which bind to the DISC 
and inhibit the activation of caspase 8.
65,67 
 The extrinsic pathway may also cause the release of 
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cytochrome-c and the induction of the intrinsic pathway through activation of BID, which serves 
as a substrate for caspase 8. Upon the activation of the DISC, truncated BID (tBID) translocates 
to the mitochondria and induces the release of apoptotic proteins from the inter membrane space 
into the cytosol.
63, 65, 71 
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Figure 3: The intrinsic and extrinsic apoptotic pathways.
74
 The intrinsic pathway is 
controlled by the Bcl-2 family of proteins that induce the release of cytochrome-c from the inter-
membrane space of mitochondria in to the cytosol. Cytochrome-c causes Apaf-1 to bind and 
activate initiator caspase 9. Cleaved caspase 9 then activates executioner caspase 3. The extrinsic 
pathway is initiated by binding of TNFs to TNFRs that recruit adaptor proteins that can bind and 
activate initiator caspases 8 and 10. These initiator caspases in turn activate caspases 3 and 7. 
Caspase 8 also activates BID, which can translocate to the mitochondria and induce the release 
of cytochrome-c.  
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Autophagy 
 Autophagy is another mechanism that is tasked with maintaining cellular homeostasis, 
and this happens through the regular recycling and turnover of cytoplasmic components. This 
process is a multifunctional pathway associated with not only the removal of damaged 
organelles, but as a method of programmed cell death and various physiological and pathological 
processes that include: normal development, aging, cancer, and neurodegenerative diseases.
75, 76, 
77, 78, 79 
 Where apoptosis is an irreversible form of cell death, autophagy can lead to either cell 
death or, paradoxically, it can allow cells to escape death and therefore can be considered a 
protective mechanism at times.
80 
 An organelle called the lysosome contains hydrolytic enzymes that give it the ability to 
degrade cellular components and whole organelles.
75
 The process of getting these cellular 
components to the lysosome is collectively referred to as autophagy. There are three distinct 
categories of autophagy: microautophagy, chaperone-mediated autophagy and macroautophagy. 
Microautophagy involves the direct engulfment of cytoplasmic components by the lysosome 
through an invagination of the lysosomal membrane.
75, 76, 81
 Cytoplasmic proteins that are to be 
degraded may contain specific motifs that are recognized by lysosomal receptors, leading to 
chaperone-mediated autophagy.
75, 75, 81
 Macroautophagy, henceforth referred to simply as 
autophagy (figure 4), is the main method of turnover for cytoplasmic components, such as long-
lived macromolecules and organelles. The process of autophagy begins with sequestration of 
cytoplasm into the isolation membrane, that goes on to become a double-membrane vesicle 
called the autophagosome. The autophagosome fuses with the lysosome and at this point the 
inner membrane of the autophagosome and its contents are degraded by the hydrolases present 
within the lysosome.
82,83
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 To elucidate the molecular mechanisms that underlie the process of autophagy, 
mutagenesis-based genetic screens have been performed in yeast. These studies have revealed a 
host of genes not only in yeast, but in mammals that are responsible for the regulation of the 
autophagic response, termed autophagy-related genes (ATG).
75, 76
 It has been observed that 
autophagy is a highly conserved evolutionary process and there are many homologues with 
similar functionality in the mammalian system.
75, 76
  
 Three different signaling complexes and pathways are integral to the development of an 
autophagic response: including the mammalian target of rapamycin (mTOR) signaling pathway, 
the ATG1 complex and the class III phosphoinositide 3-kinase (PI3KC3) complex. mTOR is a 
serine/threonine kinase that is responsible for sensing changes in nutrient conditions to control 
multiple cellular processes. In respect to autophagy, mTOR is responsible for causing changes in 
the phosphorylation of ATG13. Under nutrient-rich conditions, mTOR activation causes 
hyperphosphorylation of ATG13, preventing its association with the mammalian orthologue of 
ATG1 known as ULK1 (Unc51-like kinase 1).
75, 77
 However, under starvation conditions 
mTOR’s inhibitory affects are inhibited, causing hypophosphorylation of ATG13, leading it to 
interact with ULK1. Activated ULK1 is recruited by ATG14L to directly phosphorylate Beclin-1 
(ATG 6) and induce activation of the PI3KC3 complex. The PI3Ks represent a family of 
enzymes that are implicated in an array of diverse cellular processes, such as intracellular 
trafficking, proliferation and assembly of cytoskeletal elements.
84
 Activated PI3KC 
phosphorylates phosphoatidylinositol (PI) to produce phosphatidylinositol 3-phosphate (PI3P) 
that serves as an anchor for PI3P-binding proteins, such as ATG18 to bind and form 
phagophores.
85
 Studies show that there are two different PI3KC complexes: complex one is 
involved in the formation of phagophores and includes PI3KC, p150, Beclin-1 and ATG14L 
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while complex two contributes to the maturation of the autophagosome and contains UVRAG 
(ultraviolet radiation resistance-associated gene) in place of ATG14L.
86, 75, 76 
 Phagophores, also known as isolation membranes, are crescent-shaped membranes that 
are extended to form double-membrane autophagosomes through a process that requires two 
ubiquitin-like (UBL) conjugation systems. These systems function similarly to the ubiquitylation 
process involved in protein degradation, and requires three enzymes: ubiquitin-activating 
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase enzyme (E3) 
(Marino, Mizushima). In the first UBL system ATG12 is activated by an E1-like enzyme ATG7, 
and forms a thioester intermediate before being transferred to ATG10, an E2-like enzyme. The 
last step involves covalently linking ATG5 and ATG12, and this conjugate non-covalently 
interacts with ATG16L to form the final complex. This complex dissociates from the membrane 
when autophagosome formation is completed.
75, 87
 
 The second UBL system involves the modification and incorporation of microtubule-
associated protein 1 Light Chain 3 (LC3) into the autophagosome membrane. The C-terminal 
region of LC3 is cleaved by ATG4 to form LC3-I and the E1-like enzyme ATG7 activates it. 
Upon activation, LC3-I is transferred to ATG3, an E2-like enzyme, and finally covalently bound 
to phosphatidylethanolamine (PE) to form the lipid-protein conjugate LC3-II. Upon formation, 
autophagosomes are fused with lyosomes to complete the protein degradation process.
75, 87
 
 As well as having the major role of recycling macromolecules and organelles during 
times of nutrient deprivation, autophagy can also take part in the degradation of misfolded 
proteins. This process is mediated by the adaptor molecule p62, which has domains that bind to 
both the ubiquitin moiety on poly-ubiquitinated misfolded proteins, as well as the LC3 on the 
autophagosome membrane. Lysosomal degradation of autophagosomes results in a decrease in 
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p62 levels, which makes p62 another  suitable marker for tracking autophagy in mammalian 
cells.
88 
 Autophagy can induce two opposing responses in cancer cells: protection leading to cell 
survival and cytotoxicity resulting in cell death. Although toxic effects of autophagy had been 
proposed to be accompanied by apoptosis, it has been demonstrated that knockdown of the anti-
apoptotic protein Bcl-2 induced caspase-independent autophagic cell death, by increasing the 
expression of Beclin1.
89
 This study ultimately suggested that autophagy can directly induce cell 
death without activating apoptotic pathways.  
 It has been documented that there is a link between autophagy and the unfolded protein 
response (UPR). Both processes are closely related as some of the signaling routes activated 
during the ER stress response are involved in stimulating autophagy.
90 
There is indication that 
the phosphorylation of eukaryotic initiation factor α (eIF2α) in the UPR is linked to the induction 
of autophagy.  
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Figure 4: An overview of the autophagic pathway.
91
 Upon release of inhibitory effects by 
mTOR, ULK1 is activated and causes the phosphorylation of Beclin1, which activates the 
PI3KC3 in complex I and induces autophagy. Autophagosome formation requires the two UBL 
conjugation systems. UBL system 1 produces ATG5-ATG12-ATG16 conjugates that attach the 
isolation membranes and facilitate membrane nucleation. UBL system 2 modifies LC3 and 
incorporates the final product, LC3-II into the autophagosome membrane. The final step in this 
process is the fusion of the lysososmes with the autophagosomes, which leads to complete 
degradation of autophagosome contents.  
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Endoplasmic Reticulum Stress 
 Proteins that are targeted for the secretory pathway are folded in the lumen of the 
endoplasmic reticulum (ER) by chaperones before being transported to the golgi apparatus for 
final modification and secretion. If there is an interruption in this process, there is an 
accumulation of unfolded proteins in the lumen of the ER that causes stress on the system and is 
the trigger for the unfolded protein response (UPR) illustrated in figure 5. The UPR is a series of 
actions that collectively reduce the rate of protein synthesis and activates transcription factors 
that enhance the function of the ER.
92, 93
 There are three transmembrane proteins in the 
membrane of the ER that sense the accumulation of misfolded proteins and trigger the UPR: 
PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol requiring enzyme 1 (IRE1) and 
activating transcription factor 6 (ATF6). This sensory mechanism is mediated by the chaperone 
protein glucose regulated protein of 78 kDa (GRP78), also known as binding immunoglobulin 
protein (BiP), present in the lumen of the ER. Under normal conditions, GRP78 is bound to the 
luminal domains of PERK, IRE1 and ATF6, effectively inhibiting their function. When ER stress 
occurs, GRP78 is released to bind to the unfolded protein, leading to the activation of the three 
stress sensors. Upon activation, ATF6 is proteolytically cleaved and directly translocated into the 
nucleus to induce the expression of genes required for the UPR. However, activation of PERK 
and IRE1 is associated with the dimerization and subsequent autophosphorylation of specific 
residues on their cytoplasmic kinase domains.
92, 93
 Activated IRE1 induces the formation of the 
transcription activator spliced X-box binding protein (XBP1) through splicing of the XBP1 
messenger RNA whereas PERK phosphorylates the α subunit of eukaryotic initiation factor 2 
(eIF2α). Normally, GTP-bound eIF2α binds to methionyl-transfer RNA and enhances 
recognition of the start codon and is released from ribosomal machinery when GTP is 
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hydrolyzed. Phosphorylation of the α subunit of eIF2 inhibits the exchange of GDP and GTP; 
thus, reducing protein synthesis. Furthermore, activated PERK translationally controls the 
expression of activating transcription factor 4 (ATF4) that induces the expression of variable 
UPR-related genes involved in amino acid metabolism, regulation of oxidative stress and 
apoptosis.
93
 
 To prevent aggregation of misfolded proteins in the lumen of the ER during ER stress, 
XBP1 and ATF6 increase expression of proteins that facilitate ER-associated degredation 
(ERAD). ERAD is accomplished by retrotranslocation of misfolded proteins into the cytosol 
followed by ubiquitination and proteasomal degredation. ER stress can also induce autophagy as 
an alternate route for protein degredation.
92
 As previously stated, this process is regulated by 
p62, which has the proper domains to bind the ubiquitin moiety of the misfolded proteins as well 
as the LC3 on the autophagosomes.
88
  
 Severe ER stress can also induce apoptosis by increase the expression of the group III 
Bcl-2 family of proteins including Puma, Noxa, BIM and BID which induce the insertion of 
proapoptotic proteins Bax and Bak in the mitochondrial membrane, and consequently results in 
the release of cytochrome c.
92
 It has also been suggested that ER stress-induced apoptosis occurs 
through cleavage of caspase 4, a member of caspase 1 subfamily that localizes to the ER 
membrane.
94 
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Figure 5: The mechanism of the unfolded protein response.
74
 Upon accumulation of unfolded 
proteins in the lumen of the ER, the chaperone GRP78 (BiP) is released from the luminal 
domains of PERK, ATF6 and IRE1. These activated transmembrane proteins then trigger a 
cascade of events that collectively result in expression of UPR-related genes. Severe ER stress 
can also induce apoptosis through cleavage of ER membrane-bound caspase 4 and inducing 
caspase 9.  
 
 
 
 
22  
 
Materials and Methods 
Materials 
 For cell culture, RPMI 1640, penicillin/streptomycin, trypsin-EDTA and phosphate-
buffered saline solution (PBS) were all purchased from GIBCO (Invitrogen Life Technologies, 
Waltham, MA), and the fetal bovine serum was from HyClone Laboratories, Inc. (Thermo 
Scientific HyClone, South Logan, UT). Trypan blue solution and dimethyl sulfoxide (DMSO) 
were both obtained from Sigma Chemical (St. Louis, MO).  The drugs Sildenafil and Celecoxib, 
as well as the inhibitor  
 Recombinant adenoviruses to express constitutively activated c-FLIP-s and Bcl-xL, as 
well as dominant negative (DN) caspase 9 and DN AKT were purchased from Vector Biolabs 
(Philadelphia, PA). The DNp38 adenovirus was purchased from Cell Biolabs, Inc. (San Diego, 
CA). Validated siRNA were all purchased from QIAGEN (Valencia, CA). The opti-MEM 
reduced serum medium and the lipofectamine 2000 transfection reagent used for transfections 
was purchased from GIBCO (Invitrogen Life Technologies, Waltham, MA).  
 Antibodies were all purchased from either Cell Signaling Technologies (Worchester, 
MA) or Santa Cruz Biotechnology (Santa Cruz, CA) and were diluted 1:1000 in Odyssey infared 
imaging system blocking buffer obtained from LI-COR Biosciences (Lincoln, NE). anti-FasL, 
anti-CD95, anti- eIF2α, anti-Bcl-xL and anti-GAPDH were all purchased from Santa Cruz 
Biotechnology. The anti-ATG5, anti-Beclin 1, anti-ATF4, anti-ATF6, anti-CHOP, anti-caspase 
9, anti-FLIP, and anti-p38 (MAPK) were all purchased from Cell Signaling Technologies. 
Secondary antibodies used were IRDye 680LT Goat anti-rabbit IgG and IRDye 800CW Goat 
anti-mouse IgG, both purchased from LI-COR Biosciences (Lincoln, NE). 
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Methods 
Cell Culture 
 BT-474 and BT-549 ductal carcinoma cells were acquired from ATCC (Manassas, VA) 
and cultured in RPMI 1640. The medium was supplemented with 10% (v/v) FBS and 100 µg/mL 
(1% v/v) penicillin/streptomycin. Cells were maintained in an incubator with 5% CO2 at 37ºC. 
Drug Treatments 
 Plated cells are given a 24 hour period to establish before being treated with indicated 
concentrations of Sildenafil and/or Celecoxib. Both drugs were taken from stock solutions and 
diluted in DMSO to reach the desired concentrations. In all treatments, the maximal 
concentration of solvent did not exceed 0.02% (v/v).  
Western Blot Analysis 
 Cells were plated in 60 x 15 mm dishes and treated with the desired concentration of each 
drug for 24 hour. After incubation, cells were lysed and scraped using whole-cell lysis buffer 
(0.5 M Tris-HCL, ph 6.8 2% (v/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 0.02% 
(v/v) bromophenol blue). Collected samples were boiled for 10 minutes followed by loading onto 
8-12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). Proteins were 
electrophretically separated and transferred onto 0.45 µm PVDF membrane using the Bio-Rad 
Trans-Blot Turbo system. Membranes were blocked in Odyssey infared imaging system blocking 
buffer obtained from LI-COR Biosciences (Lincoln, NE) for an hour. Primary antibody exposure 
took place overnight at 4ºC. After washing with TBST, membranes were incubated in the correct 
corresponding secondary antibody for a minimum of 1 hour at room temperature. Membranes 
were then washed again with TBST before being visualized using the Odyssey Infared Imager 
(LI-COR Biosciences, Lincoln, NE). 
 
 
24  
 
Infection with Adenovirus 
 Cells were plated in 12-well plates and left to establish for 24 hours. Media was removed 
and replaced with 1 mL of 5% (v/v) RPMI. Recombinant adenoviruses for caBcl-xL, dnCasp9, 
C-FLIP, dnp38, dnAKT and empty vector were added at a multiplicity of infection (MOI) of 50. 
Cells were incubated for 24 hours before changing the medium to 10% (v/v) RMPI, followed by 
the addition of the indicated concentrations of each drug for 24 hours before being subjected to 
trypan blue exclusion assay.  
Plasmid and siRNA Transfections 
 Cells were plated in 12-well plates and left to establish for 24 hours. Media was removed 
and replaced with 800 µL of 5% (v/v) RPMI. For transfections, 1 µg of plasmid or 1 µL of 
siRNA was added to 100 µL of OPTIMEM per transfection and allowed to incubate for 5 
minutes at room temperature. Concurrently, 1 µL of lipofectamine in 100 µL of OPTIMEM per 
transfection was also incubated for 5 minutes at room temperature. Both solutions were then 
combined and allowed to incubate for 20 minutes at room temperature. After incubation, 200 µL 
of the solution was added to the cells, bringing the total volume per well to 1 mL. The plates 
were incubated for 24 hours before changing the medium to 10% (v/v) RPMI, followed by the 
addition of indicated concentrations of each drug for 24 hours before being subjected to trypan 
blue exclusion assay.   
 Plasmids and siRNA included the scrambled control (SCR), FASL, FADD, ATG5, 
Beclin1, ATF4, ATF6, CHOP, eIF2α, dnPERK, and caAKT. 
 
 
 
25  
 
Trypan Blue Exclusion Assay 
 The media and any unattached cells from each well of a 12-well plate were transferred to 
a 15 mL conical tube. Attached cells were collected via trypsinization with trypsin/EDTA for 2 
minutes at 37ºC. After centrifugation at 1,000 rpm for 5 minutes, most of the supernatant was 
removed, leaving approximately 50 µL to which 50 µL of trypan blue was added. The pellet was 
resuspended in the mixture and counted using a hemocytometer and a light microscope. Cell 
death was determined as a percentage of dead cells from the total number of cells counted. 
Fluorescence Cell Viability Assay 
 Cells were plated at a density of 1x10
4
 cells per well on a 96-well plate. After 24 hours 
they were drug treated and incubated for an additional 24 hours. A working solution of 2 µM 
calcein AM and 4 µM Ethidium homodimer-1 were added to the wells and the plate was 
centrifuged at 1,000 rpm for 5 minutes. The plate was then visualized using the Hermes WiScan 
(IDEA Bio-Medical LTD Atlanta, GA) to quantify cell death and for imaging. 
Colony Formation Assay 
 Varying numbers of cells were plated on 12-well plates, between 5x10
2 
and 4x10
3
, and 
the next day were drug treated with the specified concentration of drugs. The media was then 
changed after an additional 24 hours, in which the cells were left to grow. Once the control plate 
produces visible, distinct colonies, the media is carefully removed from the wells and is gently 
washed with 3 mL of PBS. The PBS is carefully aspirated, and 3 mL of methanol is added to 
each well for 10 minutes to fix the cells. The methanol is removed, and the plates are again 
washed with 3 mL of PBS. Crystal violet stain is then added for a minimum of 30 minutes. The 
stain is removed and the plates are washed with water and left overnight to dry. Upon drying, the 
colonies were counted. 
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Data Analysis 
 The effects of the various treatments were analyzed using one-way analysis of variance 
and a two-tailed Student’s t-test. Results with a P value of <0.05 were considered statistically 
significant. 
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Results 
 The drugs sildenafil (referred to as sil) and celecoxib (referred to as cel) have been 
previously used in the context of anticancer therapies. They have been utilized separately, each 
to enhance the killing capacity of standard of care treatments already in wide use. Initial 
experiments of this study were performed to demonstrate the toxicity of the combination of 2 µM 
sildenafil with 10µM celecoxib in both BT 474 and BT 549 cells lines after twenty-four hours of 
drug exposure. In each experiment the control group (referred to as vehicle or veh) is treated 
with DMSO and serves as a measure of solvent effects for comparison, as the drugs were 
dissolved in DMSO for delivery. 
 The cytotoxic effects of the drugs singularly and in combination were determined by 
using the trypan blue exclusion assay, which is considered a measure of cell viability. As seen in 
figure 6, sildenafil alone caused a minimal increase in cell death when compared to the vehicle, 
yet celecoxib caused an increase in cell death as a singular agent from the vehicle at an average 
of 8% to an average of 12% in both cell lines. There was a significant increase in cell death 
(P<0.05 compared to vehicle) in the drug combinations of both cell lines, with an even larger 
response witnessed in the BT 474 cells at about 22% cell death in comparison to the response 
seen in the BT 474 cells at 18%.  
 It was observed that there was an increase in blebbing and cell debris in treated cells 
when compared to control cells, present in both cell lines during their assessments of cell 
viability using trypan blue. To better visualize the physical characteristics of cell death, 
morphological changes induced by the drugs were characterized by utilizing the fluorescence cell 
viability assay. In the BT 474 cells shown in figure 7 and the BT 549 cells in figure 8, there was 
an increase in cell death across the treatments, as indicated by the increase in red stained cells. 
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Also of note was the decrease in total cells visualized upon treatment, suggesting a potential 
cytostatic effect. The combination of 2µM sildenafil and 10 µM celecoxib in the BT 474 cells in 
7D illustrated cell elongation and large amounts of cell fragmentation. The BT 549 cells in figure 
8D did not illustrate as much cell fragmentation, in agreement with the decreased percentage of 
cell death upon comparison with the combination treated BT 474 cells.  
 For an assessment of a longer term response to the sildenafil and celecoxib combination, 
a colony assay was performed to determine long term cell survival following twenty-four hours 
of drug treatment. Colony formation illustrates the ability of the cells to survive for a period of 
time following exposure to the drugs, with cells that survive the treatment continuing to grow 
and produce colonies. As seen in figures 9 and 10, both BT 474 and BT 549 cells responded to 
treatment in a similar fashion, with a decrease in cell survival upon increasing concentrations of 
both sildenafil and celecoxib, as single agents and in combination. The BT 474 cells illustrated 
greater toxicity to both sildenafil and celecoxib overall in comparison to the BT 549 cells; cell 
death increased from 24% or 12%  with 2 µM sildenafil to 40% or 32%  with 10 µM celecoxib, 
and the combination of the two caused an even further increase in death to 47% and 36%, 
respectively. Taken together with the previous cell death assays performed, this combination of 2 
µM sildenafil and 10 µM celecoxib induced a significantly (* P<0.05 compared to vehicle) 
increased amount of cell death, working more effectively together than as independent agents. 
  
 
 
A 
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Figure 6: Assessment of cell viability in BT 474 and BT 549 cells treated with sildenafil and 
celecoxib. Cells were treated with DMSO, sildenafil (2µM), celecoxib (10µM) or combination 
for 24 hours and then subjected to trypan blue exclusion assay to determine cell viability.  
* P<0.05 compared to vehicle. 
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Figure 7: Sildenafil and celecoxib cell death visualization in BT 474 cells. BT 474 cells were 
treated with DMSO (panel A), sildenafil (2µM, panel B), celecoxib (10µM, panel C) or 
combination (panel D). After 24 hours they were visualized using the fluorescence cell viability 
assay protocol. Green is indicative of live cells (calcein), while red indicates dead cells 
(ethidium).  
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Figure 8: Sildenafil and celecoxib cell death visualization in BT 549 cells. BT 549 cells were 
treated with control DMSO (panel A), sildenafil (2µM, panel B), celecoxib (10µM, panel C) or 
combination (panel D). After 24 hours they were visualized using the fluorescence cell viability 
assay protocol. Green is indicative of live cells (calcein), while red indicates dead cells 
(ethidium). 
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Figure 9: Colony formation assay in BT 474 cells. Cells were treated with indicated µM 
concentrations of sildenafil or celecoxib once for a twenty-four hour period and allowed to grow 
colonies for seven days before fixing and staining with crystal violet to asses cell survival.          
* P<0.05 compared to vehicle. ** P<0.05 comparison between celecoxib at 10 µM and the 
combination of 2µM sildenafil and 10 µM celecoxib. 
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Figure 10: Colony formation assay in BT 549 cells. Cells were treated with indicated µM 
concentrations of sildenafil or celecoxib once for twenty-four hours and allowed to grow 
colonies for a week before fixing and staining with crystal violet to asses cell survival.  
* P<0.05 compared to vehicle. ** P<0.05 comparison between celecoxib at 10 µM and the 
combination of 2µM sildenafil and 10 µM celecoxib. 
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Mechanistic Determination of Induced Cell Death 
 To investigate the mechanism of action of cell death seen in the combination of 2 µM 
sildenafil and 10 µM celecoxib, the expression of various proteins involved in the three major 
cell death pathways previously mentioned were modulated to assess their involvement in the 
sildenafil and celecoxib-mediated cell death observed in both BT 474 and BT 549 cell lines. 
 For the determination of the possible invovement of apoptosis, some key components of 
both the intrinsic and extrinsic pathways were modulated. For intrinsic apoptosis, cells were 
infected with adenoviruses carrying an empty vector (CMV) or constructs designed to either up-
regulate Bcl-xL (caBcl-xL) through consititutive activation  or downregulate caspase 9 via 
dominant negative mutation (dn Casp9). Cells were infected and then treated with 2µM sildenafil 
and/or 10 µM celecoxib for twenty-four hours before they were subjected to trypan blue exlusion 
assay to assess cell death. Both cell lines demonstrated a decrease in cell death upon infection of 
both intrinsic mediators as seen in figures 11 and 12. The control in both the BT 474 and BT 549 
cells illustrated an average of 21% cell death in the combination, while both cell lines produced 
an average of 15% cell death in the combination in both caBcl-xL and dnCasp9.  
 Involvement of the extrinsic aspect of apoptosis was assessed by siRNA mediated 
downregulation of FasL and CD95, with a scrambled nonspecific siRNA as control (siSCR), as 
well as viral up-regulation of FLIP (c-FLIP). Cells were infected or transfected and then treated 
with 2µM sildenafil and/or 10 µM celecoxib for twenty-four hours before they were subjected to 
trypan blue exlusion assay to assess cell death. As seen in figures 11, 12 the increase in FLIP 
expression caused a decrease in cell death from an average of 21% in the control to 15% in both 
BT 474 and BT 549 cells. As illustrated in figure 13, the knockdown of both FasL and CD95 
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resulted in decreased cell death. The combination treatment in the siSCR transfected BT 474 
cells had cell death averaged at 27% while cell death was measured to be 23% in the BT 549 
cells, and both produced significant decreases (* P<0.05 compared to vehicle) in the 
combination treatments after the knockdown of both FasL (21% and 19%, respectively) and 
CD95 (both 15%).  
 Cell death through autophagic response was explored by using siRNA downregulation of 
ATG5 and Beclin1. Cells were transfected with the SCR control, ATG5 or Beclin1 and then 
treated with 2µM sildenafil and/or 10 µM celecoxib for twenty-four hours before they were 
subjected to trypan blue exlusion assay to assess cell death. As illustrated in figure 14, 
downregulation of ATG5 and Beclin1 decreased cell killing in both BT 474 and BT 549 cells. 
The cell death in the siSCR transfected cells upon treatment with the combination was 24% in 
both cell lines, yet illustrated slightly different decreases in cell death. There was an overall 
decrease in death seen with both ATG5 and Beclin1 knockdown, yet the BT 474 cells produced 
17% and 19% changes, respectively, while treatment of the BT 549 cells gave 21% and 17% cell 
killing in ATG5 and Beclin1 knockdowns.  
 For assessing the involvement of the ER stress response,  ATF4, ATF6, CHOP and eIF2α 
were all downregulated through siRNA-mediated knockdown. Cells were transfected and then 
treated with 2µM sildenafil and/or 10 µM celecoxib for twenty-four hours before they were 
subjected to trypan blue exlusion assay to assess cell death. In both BT 474 and BT 549 cell 
lines, all transfections showed an overall decrease in cell death, as illustrated in figures 15 and 
16. The siSCR transfected cells in both cell lines had an average of 20% cell death, with the 
combination treatment in every siRNA-mediated knockdown producing a combination cell death 
at an average of 15%. Another protein implicated in the ER stress response, p38 MAPK, was 
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investigated through viral infection of the dominant negative mutation of p38 MAPK 
(dnp38).This protein is an upstream regulator of CHOP, and was illustrated to have caused a 
decrease in cell death, as demonstrated in figures 11 and 12.The CMV infected cells for both BT 
474 and BT 549 cell lines upon treatment with the combination had on average 21% cell death, 
and the combination treatment in both cell lines upon knockdown of p38 MAPK produced an 
average of 15% cell death. 
The AKT signaling pathway is implicated in cell proliferation, growth and survival, as 
well as regulating apoptosis. Using either plasmid or viral infection, AKT was downregulated 
using the dominant negative mutation, and upregulated by mutating it to be constitutively active. 
Cells were infected or transfected and then treated with 2µM sildenafil and/or 10 µM celecoxib 
for twenty-four hours before they were subjected to trypan blue exlusion assay to assess cell 
death. Increasing the expression of AKT caused a protective effect and downregulating it caused 
an increase in cell death as seen in figure 17. The control combination treatment in both cell lines 
produced cell death of about 18%, with caAKT causing a decrease in death to about 15% and 
dnAKT increasing cell death to an average of 27% in both BT 549 and BT 474 cell lines.  
All experiments performed illustrated the same characteristic response profile that was 
observed in figure 6. It was observed that 2µM sildenafil is seen to have a marginal increase in 
cell death that was not significantly different from control, celecoxib as a single agent causes a 
significant increase in cell death, with the combination of 2µM sildenafil and 10 µM celecoxib 
producing the highest amount of cell death in all experiments, comparatively. 
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Figure 11: Viral regulation of Bcl-xL, caspase 9, C-FLIP and p38 downregulated drug 
combination-mediated toxicity in BT 474 cells. Cells were first infected with their respective 
virus and then treated with vehicle, 2µM sildenafil, 10 µM celecoxib, or combination. Cell 
viability was determined by trypan blue exclusion assay 24 hours after treatment. *P <.005 less 
than corresponding value of CMV cells. 
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Figure 12: Viral regulation of Bcl-xL, caspase 9, C-FLIP and p38 downregulated drug 
combination-mediated toxicity in BT 549 cells. Cells were first infected with their respective 
virus and then treated with vehicle, 2µM sildenafil, 10 µM celecoxib, or combination. Cell 
viability was determined by trypan blue exclusion assay 24 hours after treatment. *P <.005 less 
than corresponding value of CMV cells. 
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Figure 13: Knockdown of FasL and CD95 reduced drug combination-mediated toxicity. 
Cells were first transfected with either siFasL or siCD95 and then treated with vehicle, 2µM 
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue 
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than 
corresponding value of siSCR cells. 
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Figure 14: Knockdown of ATG5 and Beclin1 reduced drug combination-mediated toxicity. 
Cells were first transfected with siATG5 or siBeclin 1and then treated with vehicle, 2µM 
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue 
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than 
corresponding value of siSCR cells. 
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Figure 15: Knockdown of ATF4 and ATF6 reduced drug combination-mediated toxicity. 
Cells were first transfected with either siATF4 or siATF6 and then treated with vehicle, 2µM 
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue 
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than 
corresponding value of siSCR cells. 
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Figure 16: Knockdown of CHOP and eIF2α reduced drug combination-mediated toxicity. 
Cells were first transfected with either siCHOP or sieIF2α and then treated with vehicle, 2µM 
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue 
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than 
corresponding value of siSCR cells. 
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Figure 17: Modulation of AKT casused changes in levels of cell death. Cells were first 
infected or transfected and then treated with vehicle, 2µM sildenafil, 10 µM celecoxib, or 
combination. Cell viability was determined by trypan blue exclusion assay 24 hours after 
treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than corresponding value of siSCR 
cells. 
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Discussion 
 Targeted therapies common in treating breast cancer have been generally focused on 
hormone and growth receptor pathways, due to the changes in regulation of the receptor 
pathways in different types of breast cancers. However, it has been demonstrated that it is 
common for resistances to these treatments to form, thus alternative treatment options are 
necessary. 
 Doxorubicin, like many chemotherapeutic agents causes cardiotoxic effects, and upon 
supplementation with 10 µM of sildenafil there appeared to be attenuation of this severe side 
effect.
51
 However, upon further investigation sildenafil was shown to enhance cell death by 
apoptosis through caspase 9 activity in prostate cancer when paired with doxorubicin treatment.
51
 
It was later demonstrated that sildenafil facilitates cytotoxic chemotherapy killing dependent on 
the activation of apoptosis through the extrinsic pathway via death receptors in pediatric CNS 
tumors.
52
  
 The tumorigenic potential of COX-2 overexpression has frequently been associated with 
a resistance to apoptosis, due to the upregulation of AKT signaling.
95
 It was believed that 
celecoxib treatment can inhibit AKT signaling, and thus increase apoptosis through its inhibitory 
effects on COX2.
61, 96, 97, 98, 99, 100,101 
 However, a drug called OSU-03012 was developed using 
celecoxib as the chemical backbone, yet lacking COX-2 inhibitory activity.
100
  Cell death upon 
treatment with OSU was found to be linked to the AKT pathway, with OSU supressing 
phosphorylation of AKT.
100
 Yet other studies have shown that the toxicity produced by OSU was 
not closely correlated with the suppression of AKT signaling, indicating other methods of killing 
may be involved.
102
 It was later elucidated that both autophagy and ER stress played a role in 
OSU lethality, with knockdown of ATG5 and Beclin1 suppressing cell killing as well as the 
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supression of BiP, that causes a PERK-dependent autophagic response.
103, 104
 This demonstrated 
that celecoxib may be killing through apoptosis via the AKT pathway since it is indicated both in 
cells treated with celecoxib as well as OSU, yet also regulating autophagy and ER stress in a 
COX-independent manner. 
 Further studies demonstrated  that the intrinsic pathway is involved in cell death upon 
treatment with celecoxib.
105
 It has been observed that there is a decrease in expression of 
antiapoptotic proteins such as Bcl-2 and Bcl-xL, and expression of the proapoptotic protein Bad 
increases upon treatment, causing the release of cytochrome c from the mitochondria and 
inducing caspases 3, 8, and 9.
105, 106, 107, 108
The extrinsic pathway was noted to be activated as 
well, through FasL and CD95signaling  in celecoxib treated cervical carcinoma cells.
109, 110, 111
 
Celecoxib treatment also increases ceramide levels in mammary tumor cells, and increases in 
ceramide levels are associated with the induction of apotosis.
112, 113, 114, 115
 It has been shown that 
ceramide is important for the generation of receptor clusters, including CD95 clustering, and it 
constitutes an important prerequisite for receptor signaling.
116 
  Results of the studies performed in this manuscript indicated that 2 µM sildenafil and 10 
µM celecoxib worked better in combination than individually to promote cell killing in both BT 
474 and BT 549 breast cancer cell lines, with a higher toxicity illustrated in BT 474 cells (figures 
6-10). Through various modulations of key players in cell death pathways, it is suggested that the 
extrinsic, receptor-mediated pathway of apoptosis may be the major effector of cell death in this 
drug combination. The downregulation of FasL and CD95 in figure 13 illustrates the production 
of a larger protective effect from cell death when compared to other knockdowns. The over-
expression of FLIP, an inhibitor that blocks the activation of caspase 8, also shows a protective 
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effect (figure 11), further indicating the role of the extrinsic apoptotic pathway in cell death via 
the combination of 2 µM sildenafil and 10 µM celecoxib. 
 There was a less pronounced change in cell death present through the changes in 
autophagy and ER stress, yet the downregulation of proteins involved in these pathways 
suggested that they too are playing a role in cell death mediated by the drug combination of 
sildenafil and celecoxib. The decrease in cell death seen after knockdown of ATG5 and Beclin1 
in figure 14 coincides with the literature produced on OSU, as well as the results on the induction 
of ER stress. While PERK itself was not used in these experiments, the protective effects of 
siRNA-mediated knockdown of eIF2α, a down stream target of PERK, and ATF4 (figures 15 
and 16) which is acted on by eIF2α may implicate a dependence on PERK signaling in the ER 
stress response as well as the induction of ATF6 and p38 MAPK to act on CHOP. Modulation of 
AKT signaling also followed what is expected of celecoxib treatment, in that further reduction in 
AKT signaling through dominant negative downregulation increased cell death, while increasing 
its activation decreased cell killing. 
 It is commonly seen in the literature that these drugs are used at non-clinically relevant 
doses, such as 10µM sildenafil and 50 µM celecoxib.
51, 60, 100
 The concentrations used in these 
experiments are within the clinically acheiveable range, and still induced cell death. This was 
further verified by unpublished data that has since been produced in the lab, when 2µM silenafil 
and 10µM celecoxib was used in vivo and the combination was successful in slowing the 
progresssion of tumor growth in athymic nude mice. Our lab has also recently produced results 
that indicated the combination of 2µM sildenafil and 10 µM celecoxib is capable of killing in a 
number of other cancers, including brain and colon. Ceramide assays have also been performed, 
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and results indicate that ceramide levels do indeed increase with celecoxib treatment as expected, 
and the effect is even further enhanced when sildenafil is added to the treatment in combination. 
 Taken together, the results presented in this manuscript agree with the literature on the 
potential mechanisms of cell death induced by celecoxib, and indicates that the addition of 2 µM 
sildenafil upon treatment with 10 µM celecoxib enhances toxicity through the induction of ER 
stress, autophagy, and both apoptotic pathways, with a larger emphasis on the extrinsic pathway. 
It is a novel combination with a multi-pronged approach  to the treatment of breast cancer 
specifically, with implications for future work in multiple types of cancer. 
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